Saturday 17 October 2026
Export CLDI’s income statement to Excel — free account
Calidi Biotherapeutics, Inc.
CLDI Healthcare Biotechnology
Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00. In the quarter to June 2026, EPS grew 90.8%, free cash flow grew 11.2% and total debt fell 7.87%, each against the same quarter a year earlier.
0.84
0.03
−3.45%
Follow CLDI
Calidi Biotherapeutics, Inc. (CLDI) P/E ratio
Calidi Biotherapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 106× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 106×
Ten-year median
0.0×
Current reading's percentile
67
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| GRI GRI Bio, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)